Skip to main content

-

FPDI-2013-18322

•
Funding agency name Ministerio de Ciencia e Innovación
Funding agency acronym MICINN
Program Programa Estatal de Promoción del Talento y su Empleabilidad en I+D+i
Subprogram Subprograma Estatal de Formación
Call Contratos para la Formación Posdoctoral
Call year 2013
State Plan 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Management unit Secretaría de Estado de Educación, Formación Profesional y Universidades
Beneficiary centre INSTITUT DE RECERCA BIOMEDICA DE LLEIDA, FUNDACIO PRIVADA DR. PIFARRE

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Activated leukocyte cell adhesion molecule (ALCAM) is a marker of recurrence and promotes cell migration, invasion, and metastasis in early-stage endometrioid endometrial cancer

  • Devis, Laura
  • Santacana, María
  • Palacios Calvo, José
  • Moreno-Bueno, Gema
  • Abal, Miguel
  • Matías-Guiu, Xavier
  • Reventós, Jaume
  • Colas, Eva
Endometrial cancer is the most common gynaecological cancer in western countries, being the most common subtype of endometrioid tumours. Most patients are diagnosed at an early stage and present an excellent prognosis. However, a number of those continue to suffer recurrence, without means of identification by risk classification systems. Thus, finding a reliable marker to predict recurrence becomes an important unmet clinical issue. ALCAM is a cell–cell adhesion molecule and member of the immunoglobulin superfamily that has been associated with the genesis of many cancers. Here, we first determined the value of ALCAM as a marker of recurrence in endometrioid endometrial cancer by conducting a retrospective multicentre study of 174 primary tumours. In early-stage patients (N = 134), recurrence-free survival was poorer in patients with ALCAM-positive compared to ALCAM-negative tumours (HR 4.237; 95% CI 1.01–17.76). This difference was more significant in patients with early-stage moderately–poorly differentiated tumours (HR 9.259; 95% CI 2.12–53.47). In multivariate analysis, ALCAM positivity was an independent prognostic factor in early-stage disease (HR 6.027; 95% CI 1.41–25.74). Then we demonstrated in vitro a role for ALCAM in cell migration and invasion by using a loss-of-function model in two endometrial cancer cell lines. ALCAM depletion resulted in a reduced primary tumour size and reduced metastatic local spread in an orthotopic murine model. Gene expression analysis of ALCAM-depleted cell lines pointed to motility, invasiveness, cellular assembly, and organization as the most deregulated functions. Finally, we assessed some of the downstream effector genes that are involved in ALCAM-mediated cell migration; specifically FLNB, TXNRD1, and LAMC2 were validated at the mRNA and protein level. In conclusion, our results highlight the potential of ALCAM as a recurrent biomarker in early-stage endometrioid endometrial cancer and point to ALCAM as an important molecule in endometrial cancer dissemination by regulating cell migration, invasion, and metastasis., This work was funded by Instituto de Salud CarlosIII, grant PI14/02043, co-financed by the European Regional Development Fund (ERDF), and was also supported by the Spanish Ministry of Health (RD12/0036/0035), the AECC (Grupos Estables de Investigacion 2011-AECC-GCB 110333 REVE), the Fundació La Marató TV3 (2/C/2013), and the CIRIT Generalitat de Catalunya (2014 SGR 1330). A Spanish Ministry of Economy and Competitiveness grant (FPDI-2013-18322) was awarded to Dr Colás., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Chromatin remodelling and DNA repair genes are frequently mutated in endometrioid endometrial carcinoma

  • García-Sanz, Pablo
  • Mota, Alba
  • Pérez López, María
  • Colas, Eva
  • López-López, Rafael
  • Abal, Miguel
  • Reventós, Jaume
  • Matías-Guiu, Xavier
  • Moreno-Bueno, Gema
In developed countries, endometrial carcinoma is the most common cancer that affects the female genital tract. Endometrial carcinoma is divided into two main histological types, type I or endometrioid and type II or non-endometrioid, each of which have characteristic, although not exclusive, molecular alterations and mutational profiles. Nevertheless, information about the implication and relevance of some of these genes in this disease is lacking. We sought here to identify new recurrently mutated genes in endometrioid cancers that play a role in tumourigenesis and that influence the clinical outcome. We focused on low-grade, non-ultramutated tumours as these tumours have a worse prognosis than the ultramutated POLE-positive endometrioid endometrial carcinomas (EECs). We performed exome-sequencing of 11 EECs with matched normal tissue and subsequently validated 15 candidate genes in 76 samples. For the first time, we show that mutations in chromatin remodelling-related genes (KMT2D, KMT2C, SETD1B and BCOR) and in DNA-repair-related genes (BRCA1, BRCA2, RAD50 and CHD4) are frequent in this subtype of endometrial cancer. The alterations to these genes occurred with frequencies ranging from 35.5% for KMT2D to 10.5% for BRCA1 and BCOR, with some showing a tendency toward co-occurrence (RAD50-KMT2D and RAD50-SETD1B). All these genes harboured specific mutational hotspots. In addition, the mutational status of KMT2C, KMT2D and SETD1B helps to predict the degree of myometrial invasion, a critical prognostic feature. These results highlight the possible implication of these genes in this disease, creating opportunities for new therapeutic approaches., Grant sponsor: AECC (Grupos Estables de Investigacion); Grant number: 2011-AECC-GCB 110333; Grant sponsor: Instituto de Salud Carlos III; Grant numbers: PI13/00132, PI16/00134, RETIC-RD12/0036/0007, RETIC-RD12/0036/0035, PI13/01701, RD12/0036/0013, PI14/02043, PI14/01942; Grant sponsor: “CIRIT, Generalitat de Catalunya”; Grant numbers: 2014 SGR 1330, 2014 SGR 138; Grant sponsor:GEIS award 2013; Grant sponsor: “Comunidad de Madrid”; Grant number: S2010/BMD-2303; Grant sponsor: Telemarató; Grant number:TV3 2013; Grant sponsor: AECC Scientific Foundation; Grant sponsor: UAM; Grant number: FPI-UAM 2014; Grant sponsor: Spanish Ministry of Education, Culture and Sports; Grant number: FPU2012-5338; Grant sponsor: Spanish Ministry of Economy and Competitiveness; Grant number: FPDI-2013–18322., Peer Reviewed
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Exosome-like vesicles in uterine aspirates, a comparison of ultracentrifugation-based isolation protocols

  • Campoy Moncayo, Irene|||0000-0001-7411-5706
  • Lanau Angulo, Lucia
  • Altadill, Tatiana
  • Sequeiros, Tamara|||0000-0002-0908-2263
  • Cabrera Díaz, Silvia|||0000-0002-3164-6686
  • Cubo-Abert, Montserrat|||0000-0002-0315-1440
  • Pérez-Benavente, Assumpció|||0000-0003-1872-9003
  • Garcia, Angel
  • Borrós, Salvador|||0000-0002-4003-0381
  • Santamaría Margalef, Anna|||0000-0001-6726-8990
  • Ponce, Jordi|||0000-0002-0613-2261
  • Matías-Guiu, Xavier|||0000-0002-7201-6605
  • Reventós, Jaume
  • Gil-Moreno, Antonio|||0000-0003-1106-5590
  • Rigau, Marina|||0000-0002-1691-454X
  • Colás Ortega, Eva|||0000-0003-0302-4828
Uterine aspirates are used in the diagnostic process of endometrial disorders, yet further applications could emerge if its complex milieu was simplified. Exosome-like vesicles isolated from uterine aspirates could become an attractive source of biomarkers, but there is a need to standardize isolation protocols. The objective of the study was to determine whether exosome-like vesicles exist in the fluid fraction of uterine aspirates and to compare protocols for their isolation, characterization, and analysis. We collected uterine aspirates from 39 pre-menopausal women suffering from benign gynecological diseases. The fluid fraction of 27 of those aspirates were pooled and split into equal volumes to evaluate three differential centrifugation-based procedures: (1) a standard protocol, (2) a filtration protocol, and (3) a sucrose cushion protocol. Characterization of isolated vesicles was assessed by electron microscopy, nanoparticle tracking analysis and immunoblot. Specifically for RNA material, we evaluate the effect of sonication and RNase A treatment at different steps of the protocol. We finally confirmed the efficiency of the selected methods in non-pooled samples. All protocols were useful to isolate exosome-like vesicles. However, the Standard procedure was the best performing protocol to isolate exosome-like vesicles from uterine aspirates: nanoparticle tracking analysis revealed a higher concentration of vesicles with a mode of 135 ± 5 nm, and immunoblot showed a higher expression of exosome-related markers (CD9, CD63, and CD81) thus verifying an enrichment in this type of vesicles. RNA contained in exosome-like vesicles was successfully extracted with no sonication treatment and exogenous nucleic acids digestion with RNaseA, allowing the analysis of the specific inner cargo by Real-Time qPCR. We confirmed the existence of exosome-like vesicles in the fluid fraction of uterine aspirates. They were successfully isolated by differential centrifugation giving sufficient proteomic and transcriptomic material for further analyses. The Standard protocol was the best performing procedure since the other two tested protocols did not ameliorate neither yield nor purity of exosome-like vesicles. This study contributes to establishing the basis for future comparative studies to foster the field of biomarker research in gynecology. The online version of this article (doi:10.1186/s12967-016-0935-4) contains supplementary material, which is available to authorized users.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Development of a sequential workflow based on LC-PRM for the verification of endometrial cancer protein biomarkers in uterine aspirate samples

  • Martinez-Garcia, Elena|||0000-0003-2547-7916
  • Lesur, Antoine
  • Devis-Jauregui, Laura|||0000-0003-3736-3983
  • Campos, Alexandre
  • Cabrera Díaz, Silvia|||0000-0002-3164-6686
  • van Oostrum, Jan
  • Matías-Guiu, Xavier|||0000-0002-7201-6605
  • Gil-Moreno, Antonio|||0000-0003-1106-5590
  • Reventos, Jaume
  • Colás Ortega, Eva|||0000-0003-0302-4828
  • Domon, Bruno
About 30% of endometrial cancer (EC) patients are diagnosed at an advanced stage of the disease, which is associated with a drastic decrease in the 5-year survival rate. The identification of biomarkers in uterine aspirate samples, which are collected by a minimally invasive procedure, would improve early diagnosis of EC. We present a sequential workflow to select from a list of potential EC biomarkers, those which are the most promising to enter a validation study. After the elimination of confounding contributions by residual blood proteins, 52 potential biomarkers were analyzed in uterine aspirates from 20 EC patients and 18 non-EC controls by a high-resolution accurate mass spectrometer operated in parallel reaction monitoring mode. The differential abundance of 26 biomarkers was observed, and among them ten proteins showed a high sensitivity and specificity (AUC.